Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of “Moderate Buy” from Brokerages

Palisade Bio, Inc. (NASDAQ:PALI) has received a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $10.20.

Several equities research analysts have commented on the stock. HC Wainwright assumed coverage on shares of Palisade Bio in a report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price target on the stock. Stifel Nicolaus assumed coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target on the stock. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Wolfe Research assumed coverage on shares of Palisade Bio in a report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price target on the stock.

Palisade Bio Stock Performance

NASDAQ:PALI opened at $2.12 on Friday. Palisade Bio has a one year low of $0.53 and a one year high of $2.86. The firm has a market cap of $367.99 million, a price-to-earnings ratio of -2.10 and a beta of 1.52. The firm’s fifty day moving average is $2.00 and its two-hundred day moving average is $1.93.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, equities research analysts predict that Palisade Bio will post -0.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Seven Fleet Capital Management LP acquired a new position in shares of Palisade Bio in the fourth quarter worth about $770,000. Perceptive Advisors LLC acquired a new position in shares of Palisade Bio in the fourth quarter worth about $28,318,000. Commodore Capital LP acquired a new position in shares of Palisade Bio in the fourth quarter worth about $26,896,000. Eversept Partners LP acquired a new position in shares of Palisade Bio in the fourth quarter worth about $12,670,000. Finally, Artia Global Partners LP acquired a new position in shares of Palisade Bio in the fourth quarter worth about $4,682,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.